The aggregate proceeds of the company’s IPO and private placement were $24 million. The proceeds will be used to finance Check-Cap’s clinical program, product development and corporate purposes.
The company’s shares began trading on the NASDAQ Capital Market on Feb. 19 under the ticker symbol “CHEKI.”
The company’s product is a preparation-free, ingestible imaging capsule designed for colorectal cancer screening.
More articles on gastroenterology:
AGA to hold workshop on effective scope cleaning
RD Biomed to launch study in China to examine reflux disease diagnostic device
Dr. Amar Naik joins Loyola University Health System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.